Portzamparc Initiates Coverage of Crossject with a 'Buy' Recommendation
Portzamparc, a subsidiary of BNP Paribas, has initiated coverage of Crossject stock with a 'Buy' recommendation and a target price of €4.50. This coverage adds to the four other analysts already following the specialized pharmaceutical company.
Introduction of Coverage
Portzamparc (BNP Paribas Group) has launched coverage of Crossject stock with a report titled 'The Needle Will Soon Be a Bad Memory'. According to the analyst's note, the recommendation is 'Buy' with a target price set at €4.50. Crossject is developing ZEPIZURE®, an injectable for managing epilepsy seizures, based on its proprietary needle-free auto-injector technology, ZENEO®. The company has secured a $60 million contract from the BARDA (Administration for Strategic Preparedness and Response) of the U.S. Department of Health.
Analytical Coverage Expansion
Crossject is now followed by five analysts: Alpha Value, Invest Securities, Maxim Group, Oddo, and Portzamparc. The specialized pharmaceutical company is also developing other products for emergency situations, including treatments for allergic shocks, adrenal insufficiency, opioid overdoses, and asthma attacks.
